CD8A and neoplasm: For example, we reported that blocking β-catenin or its downstream IL-10 during the T cell priming phase led to improved anti-tumor CD8 T cell responses by DC vaccines [22], and recent studies found that blocking β-catenin synergized with anti-PD-1 immunotherapy [55,56].